HanahanDWeinbergRA: The hallmarks of cancer. Cell100: 57–70, 2000.
2.
LouisDNOhgakiHWiestlerOD: WHO Classification of Tumours of the Central Nervous System. IARC Press, Lyon2007.
3.
OhgakiHKleihuesP: Genetic pathways to primary and secondary glioblastomas. Am J Pathol170: 1445–1453, 2007.
4.
JeukenJWvan der MaazenRWWesselingP: Molecular diagnostics as a tool to personalize treatment in adult glioma patients. Technol Cancer Res Trea5: 215–29, 2006.
5.
ClaesAIdemaAJWesselingP: Diffuse glioma growth: a guerilla war. Acta Neuropathol114: 443–58, 2007.
6.
FischerIGagnerJPLawM: Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol15: 297–310, 2005.
7.
WesselingPvan der LaakJALinkM: Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy. Hum Pathol29: 352–8, 1998.
8.
JainRK: Normalization of tumor vasculature: An emerging concept in anti-angiogenic therapy. Science307: 58–62, 2005.
9.
HormigoAGutinPHRaffiS: Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers. Cancer Cell11: 6–8, 2007.
10.
di JainRKTomasoEDudaDG: Angiogenesis in brain tumours. Nature Rev Neurosci8: 610–622, 2007.
11.
BernsenHVan der LaakJKustersB: Gliomatosis cerebri: quantitative proof of vessel recruitment by cooptation instead of angiogenesis. J Neurosur103: 702–6, 2005.
12.
PopeWBLaiANghiemphuP: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology66: 1258–1260, 2006.
13.
BatchelorTTSorensenAGdi TomasoE: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11: 83–95, 2007.
14.
FinnOJ: Cancer Immunology. N Engl J Med358: 2704–2715, 2008.
15.
El AndaloussiALesniakMS: An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol8: 234–243, 2006.
16.
ZagzagDSalnikowKChiribogaL: Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest85: 328–341, 2005.
17.
De VleeschouwerSRappMSorgRV: Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery59: 988–99, 2006.
18.
De VleeschouwerSFieuwsSRutkowskiS: Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res14: 3098–104, 2008.
19.
StuppRMasonWPvan den BentMJ: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med352: 987–996, 2005.
20.
HegiMEDiserensACGorliaT: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med352: 997–1003, 2005.
21.
de GrootJFGilbertMR: New molecular targets in malignant gliomas. Curr Opin Neurol20: 712–718, 2007.
22.
MellinghoffIKWangMYVivancoI: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med353: 2012–2024, 2005.
23.
Van den BentMJKrosJM: Predictive and prognostic markers in Neuro-Oncology. J Neuropathol Exp Neurol66: 1074–1081, 2007.
24.
YipSIafrateAJLouisDN: Molecular diagnostic testing in malignant gliomas: A practical update on predictive markers. J Neuropathol Exp Neurol67: 1–15, 2008.
